What are the opening hours?

Monday 09:00 - 17:00 Tuesday 09:00 - 17:00 Wednesday 09:00 - 17:00 Thursday 09:00 - 17:00 Friday 09:00 - 17:00

Cerecin

Cerecin is a global healthcare company with almost 20 years of innovation and leadership in brain health.

17/01/2023

Team Cerecin would like to wish you a Happy Lunar New Year in 2023! May the year of the Rabbit bring prosperity and good fortune to you and your family from all of us at Cerecin. 新年快乐

13/01/2023

Another successful week at Cerecin attending the 41st Annual J.P. Morgan Healthcare Conference. Dr. Charles Stacey, President and CEO, participated on the panel on Rare and Orphan Diseases at the Neuroscience Innovation Forum in San Francisco.

07/12/2022

Cerecin today that it has received authorization from the US Food and Drug Administration for an Investigational New Drug application (IND) for CER-0001 in Infantile Spasms (IS), also referred to as West Syndrome. The authorization of the IND for IS is the third for tricaprilin, with other INDs open in Alzheimer’s disease and migraine.

The IND authorization will enable the Company to conduct the next IS study globally with trial sites in the US. For more on this news, see here: https://buff.ly/3P484hr

30/11/2022

Cerecin is attending the in San Diego from November 29 to December 2, 2022. We look forward to hearing about the latest advancements in Alzheimer's disease and discussing potential partnerships and licensing opportunities for our investigational product in and other neurological diseases.

If you're interested in meeting with Cerecin’s CEO and President, Charles Stacey, and the Cerecin team at the conference, please contact us at [email protected]. We look forward to meeting you and answering any questions you may have.

17/11/2022

Today, Cerecin announced the appointment of Mr. Brian Young-Hoon Kim as Head of Investor Relations with immediate effect. The appointment is part of the company’s strategic expansion into the Korean market, with the recent opening of its new office in Seoul.

Mr. Kim will oversee Cerecin's investor relations activities and build relationships with key investors and partners in Korea. He brings a wealth of experience and a strong network of relationships across the investment community. His deep understanding of the biotechnology industry and capital markets will be invaluable as Cerecin continues to advance our ongoing clinical development programs.

Read the full press release here: https://buff.ly/3EFvcPQ

03/11/2022

Today, Cerecin announced that a poster showcasing new data on investigational CER-0001 in Infantile Spasms has been accepted for virtual oral presentation at the hybrid International League Against Epilepsy EME Congress, held in Riyadh from November 16-19, 2022.

The data will be presented by Cerecin’s Chief Medical Officer, Dr. Marc Cantillon.

31/10/2022

Cerecin today announced data from the RELIEF study, a pilot study assessing the safety and efficacy of the investigational compound CER-0001 in participants with migraine, which showed a positive efficacy signal. The outcome supports the advancement of CER-0001 into a pivotal global Phase 2/3 dose-ranging study in 2023.

For more on this news, see here: https://buff.ly/3Wfbv8a

12/10/2022

Cerecin’s Chief Medical Officer, Dr. Marc Cantillon, will be presenting at the Targeting Metabesity 2022 on October 13, 1:45-2:00pm (EST) during the Emerging Company showcase session.

Dr. Cantillon will give a company presentation on Cerecin’s work in advancing the areas of neurometabolism, particularly in CNS and Alzheimer’s Disease.
Register for the conference at this link: https://buff.ly/3yAHcP7

10/10/2022

Today, Cerecin announced the appointment of Dr. Marc Cantillon as Chief Medical Officer.

Dr. Cantillon is a senior biopharmaceutical leader with over 20 years of experience in global clinical development at some of the world’s leading biotech and pharmaceutical companies. Most recently, Dr. Cantillon served as Chief Medical Officer for Reviva Pharmaceuticals, a genomics company with a focus on CNS and metabolic disease, where he was responsible for transitional clinical development, regulatory filings, orphan drug and intellectual property registrations, and fundraising.

With his wealth of experience in the biotechnology industry, particularly in CNS and Alzheimer’s disease, Dr. Cantillon is well-equipped to help Cerecin advance its clinical programs. Cerecin is excited to have him join the team and looks forward to his contributions to the company.

Read the full press release here: https://buff.ly/3ViqaPx

04/10/2022

In a CNBC International Squawk Box interview this morning, Charles Stacey, President and CEO of Cerecin, informed viewers about Cerecin’s successful financing round, and shared how the funds will support development plans CER-0001 (tricaprilin) in Alzheimer’s Disease, migraine and epilepsy as well as building Cerecin’s pipeline of novel compounds.

This investment reflects increasing regional interest in this new frontier of neuroscience and investor’s impetus for novel targets. Cerecin is pleased to add leading institutional investors from South Korea, to its existing base of Fortune 500 investors, who share the vision of building a company in the field of neurometabolism.

29/09/2022

Cerecin is pleased to announce our closing of a Series IIB funding round which was led by SK Securities and KNT Investment.

This investment will be used to advance the current clinical studies in migraine prevention and infantile spasms as well as finalize plans for a pivotal study in Alzheimer’s disease.

For more on this news, see here: https://buff.ly/3M6ghAl

22/07/2022

Each year, on July 22, the world celebrates World Brain Day to increase awareness of and support for brain health.

Cerecin is proud to join in the global effort in reducing the burden of brain disorders for everyone. As a neurology-focused biotech company, we are developing novel treatments for people around the world battling neurological diseases.

Address

8 Shenton Way
Singapore
068811

Opening Hours

Monday	09:00 - 17:00
Tuesday	09:00 - 17:00
Wednesday	09:00 - 17:00
Thursday	09:00 - 17:00
Friday	09:00 - 17:00

Website

http://www.cerecin.com/

Alerts

Be the first to know and let us send you an email when Cerecin posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cerecin:

Shortcuts

Want your business to be the top-listed Engineering Company in Singapore?